Interestingly, the combination is undergoing clinical evaluation in a phase II trial (ClinicalTrials.gov NCT04545710), started in September 2020, that has been evaluating abemaciclib combined with osimertinib in resistant EGFR mutated lung cancer patients post progression on osimertinib. This evidence concerns the gene EGFR and lung carcinoma.